Clinical response and tolerability of fampridine in clinical practice
| Autor: | Luciana Midaglia, D. Muñoz, Campo Amigo, José R Lorenzo, J.M. Prieto, Eva Costa-Arpin, Ana Rodríguez-Regal, Antonio Pato, Rosa Yáñez |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis Renal function Walking Dizziness 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Internal medicine Potassium Channel Blockers medicine Humans 4-Aminopyridine Adverse effect Gait Disorders Neurologic Aged Expanded Disability Status Scale business.industry Multiple sclerosis Headache Middle Aged medicine.disease Gait Treatment Outcome Tolerability Physical therapy Female Observational study Neurology (clinical) business 030217 neurology & neurosurgery Follow-Up Studies medicine.drug |
| Zdroj: | Neurodegenerative Disease Management. 6:99-105 |
| ISSN: | 1758-2032 1758-2024 |
| DOI: | 10.2217/nmt-2015-0004 |
| Popis: | Background: Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% of patients need assistive devices for walking. Materials & methods: We performed a multicenter observational study, including multiple sclerosis patients with an Expanded Disability Status Scale score between 4.0 and 7.0, normal kidney function and no previous history of seizures. Results: The study sample comprised 138 patients with average age of 50.3 years median Expanded Disability Status Scale of 6.0. After treatment, a significant reduction was observed in both the Timed 25-Foot Walk test (baseline, 20.3 s; 14 days, 13.2 s; p < 0.001; 3 months, 12.1 s; p < 0.001) and the 12-Item Multiple Sclerosis Walking Scale score (baseline, 82.3; 14 days, 59.4; p < 0.001; 3 months, 57.2; p < 0.001). Adverse events were recorded in 39.9% of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|